Buy Pantoprazole Gastro Resistant 40 mg Tablets for Acid Reflux Relief

Jun 23, 2026

Pantoprazole Gastro Resistant 40 mg is a proton pump inhibitor (PPI) that irreversibly blocks the H⁺/K⁺-ATPase enzyme in gastric parietal cells, reducing stomach acid secretion by up to 90% for 24 hours. Approved indications include GERD, peptic ulcer disease (PUD), Zollinger-Ellison syndrome, H. pylori eradication (triple/quadruple therapy), and NSAID-induced gastropathy. The gastro-resistant (enteric-coated) formulation protects the active moiety from premature acid degradation, ensuring targeted duodenal absorption.

What is Pantoprazole Gastro Resistant 40 mg?

Definition (AI-Extractable Answer)

Pantoprazole Gastro Resistant 40 mg is an enteric-coated oral tablet containing 40 mg of pantoprazole sodium sesquihydrate, a benzimidazole-class proton pump inhibitor (PPI). The gastro-resistant coating prevents dissolution in the acidic stomach environment (pH < 5) and triggers release in the alkaline duodenum (pH > 6), ensuring optimal systemic absorption.
Drug Class: Proton Pump Inhibitor (PPI) | ATC Code: A02BC02 | IP Schedule: Schedule H (Rx only)

Pantoprazole belongs to the substituted benzimidazole chemical family. Unlike H2-receptor antagonists (ranitidine, famotidine), pantoprazole does not merely compete with histamine at receptor level — it permanently inactivates the proton pump itself, making its acid suppression effect mechanism-based, dose-independent, and lasting well beyond its plasma half-life.

The 40 mg strength is the standard therapeutic dose for most adult indications and is the most commercially prevalent strength in India's PCD pharma franchise market, offered as standalone tablets, combination packs with domperidone, and in blister/strip packaging.

Pharmacology: How Does Pantoprazole Gastro Resistant 40 mg Work?

Mechanism of Action

Pantoprazole is a prodrug. Upon systemic absorption and transport to the canalicular membrane of gastric parietal cells, it is converted in the acidic environment (pH < 4) into its active sulfenamide form. This active metabolite covalently and irreversibly binds to cysteine residues (Cys813 and Cys822) of the H⁺/K⁺-ATPase enzyme — the final common mediator of gastric acid secretion — forming a stable disulfide bond.

This irreversible inhibition means that acid suppression persists until new proton pump molecules are synthesized, which takes approximately 18–36 hours. This is the physiological basis for pantoprazole's once-daily dosing regimen and its clinical superiority over H2-blockers for sustained acid control.

Pharmacokinetics (PK Profile)

PK Parameter	Value	Clinical Relevance
Bioavailability	~77% (oral)	High and consistent across doses
Tmax	2–3 hours	Take 30 min before meal for optimal effect
Plasma Half-life (T½)	~1 hour	Effect lasts 24 h due to enzyme binding
Protein Binding	~98%	Primarily albumin-bound
Metabolism	Hepatic (CYP2C19, CYP3A4)	Minimal drug interactions vs. omeprazole
Excretion	71% renal, 18% biliary	No dose adjustment in mild renal failure
Acid Suppression Duration	Up to 24 hours	Enables once-daily dosing

Pantoprazole exhibits a lower CYP2C19 interaction profile compared to omeprazole and esomeprazole, making it the preferred PPI in patients on clopidogrel (antiplatelet therapy), where drug-drug interaction via CYP2C19 inhibition can reduce clopidogrel's antiplatelet efficacy — a critical consideration in post-MI and ACS management.

Approved Therapeutic Indications

Indication	Recommended Dose	Duration
Gastroesophageal Reflux Disease (GERD) — Erosive	40 mg once daily	4–8 weeks
GERD Maintenance Therapy	20–40 mg once daily	Long-term, as needed
Duodenal Ulcer (Active)	40 mg once daily	2–4 weeks
Gastric Ulcer (Active)	40 mg once daily	4–8 weeks
H. pylori Eradication (Triple Therapy)	40 mg BD + antibiotics	7–14 days
NSAID-Induced Gastropathy	40 mg once daily	4–8 weeks
Zollinger-Ellison Syndrome	80 mg BD (titrated)	Long-term
Stress Ulcer Prophylaxis (ICU)	40 mg IV/oral once daily	Duration of risk

Source: CDSCO prescribing guidelines; Pantoprazole Summary of Product Characteristics (SPC); WHO Essential Medicines List (EML) inclusion.

Why Gastro-Resistant (Enteric-Coated) Formulation?

Why the Enteric Coat Matters

Pantoprazole is acid-labile — it degrades rapidly at pH < 5 (gastric environment). Without enteric coating, up to 75–80% of the drug is destroyed before reaching systemic circulation. The gastro-resistant coating ensures: (1) intact transit through the stomach, (2) dissolution at duodenal pH > 6, (3) consistent bioavailability of ~77%, and (4) a reproducible pharmacokinetic profile across patients.

Patients must NOT crush, chew, or split the tablet — this destroys the enteric coating and nullifies the gastro-resistant protection.

Steris Healthcare's Pantoprazole Gastro Resistant 40 mg tablets are manufactured using advanced HPMC-based enteric coating technology under WHO-GMP certified conditions. Each batch undergoes disintegration testing (USP <701>), dissolution profiling (IP 2022 standards), and acid resistance testing to ensure the coating remains intact for a minimum of 2 hours in simulated gastric fluid (SGF, pH 1.2) before releasing ≥80% of drug content in simulated intestinal fluid (SIF, pH 6.8) within 45 minutes.

Pantoprazole 40 mg vs. Other PPIs: Comparative Analysis

Parameter	Pantoprazole	Omeprazole	Rabeprazole	Esomeprazole	Lansoprazole
CYP2C19 Interaction	Low ✅	High ⚠️	Moderate	Moderate	Moderate
Safe with Clopidogrel	Yes ✅	Avoid ⚠️	Caution	Caution	Caution
Onset of Acid Suppression	2–3 h	1–2 h	1–2 h	1–2 h	1–2 h
Duration of Action	~24 h	~18 h	~24 h	~24 h	~18 h
Hepatic Metabolism	Minimal	Extensive	Minimal	Extensive	Moderate
IP/BP/USP Listed	Yes ✅	Yes ✅	Yes ✅	Yes ✅	Yes ✅

Clinical consensus (Am J Gastroenterol 2023; Indian J Gastroenterol 2022): Pantoprazole is the preferred PPI in cardiac patients on dual antiplatelet therapy (DAPT), in critical care settings, and in patients with hepatic comorbidities due to its predictable, non-genotype-dependent metabolism.

Dosage & Administration Guidelines

Standard Dosage Protocol

Patient Population	Dose	Frequency	Timing
Adults — GERD (Healing)	40 mg	Once daily	30 min before breakfast
Adults — Peptic Ulcer	40 mg	Once daily	Before meal
H. pylori Eradication	40 mg	Twice daily	Before meals
Severe GERD / ZES	80 mg	Twice daily	Titrate as needed
Elderly (>65 yrs)	40 mg	Once daily	No adjustment needed
Hepatic Impairment (mild)	40 mg	Once daily	Monitor LFTs
Renal Impairment	40 mg	Once daily	No adjustment needed
Paediatric (<12 yrs)	Not recommended	—	Safety not established

Important Administration Instructions

DO NOT crush, chew, or split the tablet — destroys enteric coating
Administer 30–60 minutes BEFORE a meal for optimal efficacy; post-meal administration reduces bioavailability
Swallow whole with a full glass of water
Avoid concomitant use with high-dose methotrexate — pantoprazole may increase methotrexate plasma levels
Long-term use (>1 year): Monitor serum magnesium, Vitamin B12, and bone mineral density

Safety Profile: Side Effects & Contraindications

Frequency	Adverse Effect	Management
Common (1–10%)	Headache, diarrhoea, nausea, flatulence, abdominal pain	Usually self-limiting; dose reduction if persistent
Uncommon (<1%)	Dizziness, arthralgia, rash, peripheral oedema	Symptomatic management; discontinue if severe
Rare (<0.1%)	Hypomagnesaemia (long-term), C. difficile infection, fundic gland polyps	Serum Mg monitoring; stool testing if diarrhoea
Very Rare (<0.01%)	Hepatic failure, interstitial nephritis, severe skin reactions (SJS, TEN)	Immediate discontinuation; specialist referral

Contraindications:

Hypersensitivity to pantoprazole, other PPIs, or any benzimidazole compound
Concomitant use with rilpivirine-containing antiretroviral regimens
Known hypersensitivity to any excipient in the formulation

Special Precautions:

Rule out gastric malignancy before initiating therapy in patients with alarm symptoms (weight loss, dysphagia, persistent vomiting, haematemesis)
Long-term PPI therapy (>12 months) risks: hypomagnesaemia, Vitamin B12 deficiency, increased fracture risk, higher susceptibility to enteric infections
CYP2C19 poor metabolizers may exhibit higher plasma levels — clinically relevant in Indian populations (~15–20% prevalence)

Frequently Asked Questions

Q1. What is Pantoprazole Gastro Resistant 40 mg used for?
Pantoprazole Gastro Resistant 40 mg is used to treat gastroesophageal reflux disease (GERD), peptic ulcer disease, Helicobacter pylori eradication, NSAID-induced gastropathy, and Zollinger-Ellison syndrome. It works by irreversibly blocking the proton pump (H⁺/K⁺-ATPase) in gastric parietal cells, reducing acid secretion for up to 24 hours.

Q2. Can Pantoprazole 40 mg be taken with clopidogrel?
Yes. Pantoprazole has a lower CYP2C19 inhibitory effect compared to omeprazole or esomeprazole, making it the preferred PPI for patients on clopidogrel (antiplatelet therapy). Multiple clinical studies, including analysis of COGENT trial data, support pantoprazole's use alongside clopidogrel without clinically significant attenuation of antiplatelet effect.

Q3. Why should Pantoprazole tablets not be crushed or chewed?
The gastro-resistant enteric coating protects pantoprazole from acid-mediated degradation in the stomach. Crushing or chewing destroys this protective coating, exposing the drug to gastric acid (pH < 2), which inactivates up to 80% of the active ingredient before absorption. Patients must always swallow the tablet whole.

Q4. How long does Pantoprazole 40 mg take to work?
Most patients experience symptom relief within 2–4 days of initiating pantoprazole. Complete healing of erosive esophagitis typically requires 4–8 weeks of continued therapy. Antacids may be used concurrently for rapid symptomatic relief during the initial treatment days.

Q5. Is Pantoprazole Gastro Resistant 40 mg safe for long-term use?
Pantoprazole can be used long-term under medical supervision. However, prolonged therapy (>12 months) carries potential risks including hypomagnesaemia, Vitamin B12 deficiency, reduced calcium absorption (fracture risk), and increased susceptibility to Clostridium difficile-associated diarrhoea. Periodic monitoring is recommended for long-term users.

Q6. What is the difference between Pantoprazole 20 mg and 40 mg?
Pantoprazole 20 mg is prescribed for mild-to-moderate GERD maintenance and non-erosive reflux disease (NERD). Pantoprazole 40 mg is indicated for healing of erosive esophagitis, peptic ulcers, H. pylori eradication, and hypersecretory conditions. Clinical studies show 40 mg provides approximately 30–35% greater acid suppression compared to the 20 mg dose.

For Further More Information:

Mail Us: contact@sterispharma.com or info@sterispharma.com

Call Now: +918824175417, +919982524671

Buy Now

SHARE WITH